Quest for the cure - Newsletter 2020 - Issue 1; Bladder Cancer
“Bladder cancer (BC) has the highest lifetime treatment costs per patient (pp) of all cancers, followed by colorectal-, breast-, prostate-, and lung cancer”[1] . Early stage bladder cancer, also known as non-muscle-invasive bladder cancer (NMIBC), represents 70% of new bladder cancer diagnoses and affects 1.6 million patients in Europe (treatment costs are more than €4.9 billion annually. Current NMIBC treatments (surgery, chemotherapy, immunotherapy) are suboptimal: they have significant side-effects and limited efficacy, resulting in a high tumour recurrence rate (